Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice

Antiviral Research

Volumn 79, Issue 1, 2008, Pages 71-79

  Morrey, John D ^a   Motter, Neil E ^a   Taro, Brandon ^a   Lay, Marla ^b   Fairman, Jeffery ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b Juvaris BioTherapeutics Inc   (United States)

Author keywords

Cationic lipid DNA complex; CLDC; Hepatitis B virus; Transgenic mice

Indexed keywords

ADEFOVIR DIPIVOXIL; CATIONIC LIPID DNA COMPLEX; CYTOKINE; IMMUNOLOGIC AGENT; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEPATITIS B VIRUS; INNATE IMMUNITY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS INFECTION;

ANIMALS; CYTOKINES; DIET, REDUCING; DISEASE MODELS, ANIMAL; DNA; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOLOGIC FACTORS; LIPIDS; LIVER; MALE; MICE; MICE, TRANSGENIC; VIRUS REPLICATION;

ANIMALIA; HEPATITIS B VIRUS; MUS; MUS MUSCULUS; RODENTIA;

EID: 43049134429     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.01.157     Document Type: Article

References (26)

1. Cavanaugh V.J., Guidotti L.G., and Chisari F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 71 (1997) 3236-3243
2. Dow S.W., Elmslie R.E., Fradkin L.G., Liggitt D.H., Heath T.D., Willson A.P., and Potter T.A. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum. Gene Ther. 10 (1999) 2961-2972
3. Dow S.W., Fradkin L.G., Liggitt D.H., Willson A.P., Heath T.D., and Potter T.A. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163 (1999) 1552-1561
4. Dow S.W., Schwarze J., Heath T.D., Potter T.A., and Gelfand E.W. Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Hum. Gene Ther. 10 (1999) 1905-1914
5. Gowen B.B., Fairman J., Smee D.F., Wong M.H., Jung K.H., Pace A.M., Heiner M.L., Bailey K.W., Dow S.W., and Sidwell R.W. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res. 69 (2006) 165-172
6. Guidotti L.G., and Chisari F.V. Cytokine-induced viral purging-role in viral pathogenesis. Curr. Opin. Microbiol. 2 (1999) 388-391
7. Guidotti L.G., Guilhot S., and Chisari F.V. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J. Virol. 68 (1994) 1265-1270
8. Guidotti L.G., Matzke B., Schaller H., and Chisari F.V. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69 (1995) 6158-6169
9. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., and Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 5415 (1999) 825-829
10. Gursel I., Gursel M., Ishii K.J., and Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167 (2001) 3324-3328
11. Isogawa M., Robek M.D., Furuichi Y., and Chisari F.V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79 (2005) 7269-7272
12. Iyer R.P., Jin Y., Roland A., Morrey J.D., Mounir S., and Korba B. Phosphorothioate di- and tri-nucleotides as a novel class of anti-HBV agents. Antimicrob. Agents Chemother. 48 (2004) 2199-2205
13. Iyer R.P., Roland A., Jin Y., Mounir S., Korba B., Julander J.G., and Morrey J.D. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob. Agents Chemother. 48 (2004) 2318-2320
14. Julander J.G., Sidwell R.W., and Morrey J.D. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 55 (2002) 27-40
15. Julander J.G., Colonno R.J., Sidwell R.W., and Morrey J.D. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Antiviral Res. 59 (2003) 155-161
16. Kimura K., Kakimi K., Wieland S., Guidotti L.G., and Chisari F.V. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J. Virol. 76 (2002) 10702-10707
17. Lanuti M., Rudginsky S., Force S.D., Lambright E.S., Siders W.M., Chang M.Y., Amin K.M., Kaiser L.R., Scheule R.K., and Albelda S.M. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res. 60 (2000) 2955-2963
18. Morrey J.D., Bailey K.W., Korba B.E., and Sidwell R.W. Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine. Antiviral Res. 42 (1999) 97-108
19. Morrissey D.V., Lee P.A., Johnson D.A., Overly S.L., McSwiggen J.A., Beigelman L., Mokler V.R., Maloney L., Vargeese C., Bowman K., O'Brien J.T., Shaffer C.S., Conrad A., Schmid P., Morrey J.D., Macejak D.G., Pavco P.A., and Blatt L.M. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. J. Viral Hepat. 9 (2002) 411-418
20. Raney A.K., Eggers C.M., Kline E.F., Guidotti L.G., Pontoglio M., Yaniv M., and McLachlan A. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. J. Virol. 75 (2001) 2900-2911
21. Robek M.D., Garcia M.L., Boyd B.S., and Chisari F.V. Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. J. Virol. 81 (2007) 483-491
22. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., Ohba Y., and Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448 (2007) 501-505
23. Whitmore M., Li S., and Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6 (1999) 1867-1875
24. Whitmore M.M., Li S., Falo Jr. L., and Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol. Immunother. 50 (2001) 503-514
25. Wieland S.F., Guidotti L.G., and Chisari F.V. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J. Virol. 74 (2000) 4165-4173
26. Wieland S.F., Eustaquio A., Whitten-Bauer C., Boyd B., and Chisari F.V. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc. Natl. Acad. Sci. USA 102 (2005) 9913-9917